Meister Keith A. sold $66.6M of ILMN (indirect holdings)

Meister Keith A. sold 281,433 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $236.50 ($225.12–$241.42, $66.56M total) across 13 trades over 2026-11-03 to 2026-11-04.

Original reporting
SEC EDGAR · Meister Keith A.
Published Nov 5, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
high confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishMed
01

Why it matters

The disclosed sale adds supply to the market and may trigger short‑term price weakness.

02

Market read

Insider sales of this magnitude are closely watched; traders may adjust positions ahead of the next trading session.

03

What to watch

Potential tax planning or diversification motives for the director, not necessarily a negative outlook on the business.

Relevance 6/10Novelty 8/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the director's sale.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Director Meister Keith A. sold 281,433 ILMN shares for $66.6M, reducing his stake to 488,917 shares.

Expected impact

downward pressure as the market prices in the director's sell-off

Evidence & confidence

A director disposing $66M of stock signals reduced confidence and adds supply, which typically depresses price.

Market effects

Minimal; the sale is company‑specific and does not materially affect the broader diagnostics sector.

None; impact confined to ILMN shareholders.

Low; only relevant to investors tracking Illumina.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals; price may rebound if earnings remain strong.

Key entities

  • Illumina, Inc.

    US‑listed provider of sequencing and genomic analysis tools.

  • Meister Keith A.

    Director of Illumina who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.